<DOC>
	<DOCNO>NCT02418013</DOCNO>
	<brief_summary>This study aim carry safety evaluation human cord blood frozen plasma treatment pre-frailty , ass whether treatment prevent improve age process , identify useful clinical marker frailty . The study randomize , double-blinded placebo-controlled pilot clinical Trial conduct CHA clinical trial institute .</brief_summary>
	<brief_title>Clinical Trial Evaluate Potential Efficacy Safety Human Umbilical Cord Blood Plasma</brief_title>
	<detailed_description>Assessment criterion study include ( 1 ) clinical indicators-weight loss , decrease physical activity , weak grip strength , depression ; ( 2 ) Short Physical Performance Battery ( SPPB ) ; ( 3 ) SF-36 ; ( 4 ) cardiac output ; ( 4 ) biomarkers oxidative stress , inflammation immune response ; ( 5 ) methylation ; ( 6 ) mitochondrion DNA copy number ; ( 7 ) growth factor ; ( 8 ) antioxidant capacity ; ( 9 ) hormone assay ; ( 10 ) genome assay ; ( 11 ) metabolite ; ( 12 ) safety intravenous administration . Participants randomly assign three experimental group one control group ratio 1:1:1:1 . At second visit , participant administer experimental placebo agent . Follow-up visit expect 7 day , 1 6 month first treatment . Sixth visit completion . Primary end point define severe clinical abnormality , could observe 1 month administration blood-derived product , include death , pulmonary embolism , stroke , respiratory stress hospitalization due abnormal finding laboratory test .</detailed_description>
	<mesh_term>Chlorpheniramine</mesh_term>
	<criteria>1 . Diagnosis prefrailty 2 . One two score Simple FRAIL questionnaire 3 . Aged 55 4 . Willing able hospitalize accord research plan 5 . Able participate research 12 month 6 . For woman , must diagnose menopause infertility 1 . Diagnosis irreversible disable 2 . Dementia cognitive impairment clinically relevant 3 . Unable perform task require analysis primary end point 4 . Scheduled receive organ transplantation 5 . Hemoglobin &lt; 8 g/dl ; white blood cell count &lt; 3000/mm3 ; absolute Neutrophil count &lt; 500/dl ; Thrombocyte count &lt; 80,000/mm3 ; , AST/ALT ALP &gt; 3 time normal level 6 . Hemoglobin &gt; 17g/dl male &gt; 16 g/dl female 7 . Diagnosis cancer within 5 year possibility contract cancer 8 . Anticancer chemotherapy radiation therapy 9 . History ( within 6 month ) acute diseases myocardial infarction , unstable angina , stroke , bone fracture 10 . Hormone therapy within 6 month 11 . Recent current use Immunosuppressive drug HIV patient 12 . History hospitalization due infectious disease pneumonia within one year 13 . Previous ( within one month ) current participant clinical trial 14 . Severe kidney ( eGFR &lt; 30 ) heart failure ( Class III/IV ) 15 . Any participant , opinion investigator , consider safety problem and/or perform task successfully 16 . History drug alcohol abuse 17 . Chronic Hepatitis B C : history take 18 . Known suspected pregnancy ( Women must subject pregnancy test ) 19 . Hypersensitive dimethyl sulfoxide ( DMSO )</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Frailty</keyword>
	<keyword>Umbilical cord blood</keyword>
	<keyword>Plasma</keyword>
	<keyword>Randomized trial</keyword>
	<keyword>Double-blinded trial</keyword>
	<keyword>Placebo-controlled trial</keyword>
</DOC>